AMRX vs CNS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: AMRX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMRX and CNS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMRX and CNS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Amneal Pharmaceuticals is a Bridgewater, New Jersey based biopharmaceutical company with a portfolio of roughly 300 complex generic, specialty, and biosimilar medicines that fill more than 160 million prescriptions a year, mostly in the United States. The business runs in three segments: Affordable Medicines (retail generics, injectables, and biosimilars, the largest at roughly 58% of revenue), Specialty (branded neurology and endocrinology treatments including Parkinson's disease and migraine, around 17% of revenue), and AvKARE (distribution to US federal, retail, and institutional customers, roughly 25% of revenue).

Full AMRX guide

Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT).

Full CNS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AMRX drivers: Specialty and biosimilar mix shift; Kashiv BioSciences acquisition.
• CNS drivers: Rate-cut tailwind for real assets; Return to organic growth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Amneal carries meaningful leverage, with net debt of roughly $2.5 billion and a net-debt-to-EBITDA ratio near 3.8x, which amplifies both upside and downside and limits financial flexibility. For CNS, cNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AMRX if you believe its drivers more; CNS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMRX and CNS guides.

AMRX. Amneal reaffirmed 2026 guidance of roughly $3.05 to $3.15 billion in net revenue and about $740 to $770 million in adjusted EBITDA. The stock has traded on a relatively rich earnings multiple versus generics peers, reflecting expectations for its specialty and biosimilar growth. Enterprise value of roughly $7.7 billion sits well above market cap because of the substantial debt load.

CNS. As of April 2026, CNS traded around a mid-20s price-to-earnings multiple with a dividend yield near 3.7%, reflecting its status as a profitable, dividend-paying specialty manager. Q1 2026 revenue of about $145.6 million grew roughly 8% year over year, and operating margin improved to about 34%. Because fees scale with AUM, valuation and earnings hinge on the direction of markets and flows into real-asset strategies.

Headline figures (approximate, July 2026): AMRX shows revenue (ttm) ~$3.0B, q1 2026 net revenue ~$723M (up ~4% YoY), q1 2026 adjusted ebitda ~$202M (up ~19% YoY), 2026 revenue guidance ~$3.05B to $3.15B; CNS shows assets under management ~$93.1B, revenue (q1 2026) ~$145.6M, q1 2026 net inflows ~$497M, diluted eps (q1 2026) ~$0.82.

AMRX and CNS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMRX and CNS exposure against your real portfolio. It is not an investment adviser.